A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

← catalyst calendar

NCT05831176

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

22actual

Sites

Countries

Canada, Italy, Japan +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-05-03

actual

When the study began enrolling

Primary completion

2026-02-23

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-11-25

estimated

The whole study's end, after follow-up

First posted

2023-04-26

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-01

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Eosinophilic Gastritis (EoG)
Eosinophilic Duodenitis (EoD)
Eosinophilic Gastrointestinal Disease (EGID)
Eosinophilic Gastroenteritis

Intervention

Drug: Dupilumab — also filed as DUPIXENT®, REGN668, SAR231893

Primary outcome

what the primary-completion date above is the date OF

Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)

measured Baseline up to 24 Weeks

Publications

PMID 37753954 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed